OR WAIT null SECS
Mexichem announced that it acquired the distribution and sale license for HFC-227ea/P from Du Pont.
Mexichem announced on Dec. 31, 2014 that it acquired the distribution and sale license for pharmaceutical grade HFC-227ea/P, a medical propellant, from DuPont de Nemours and Company. The product, which is used to safely deliver drugs in aerosol form, will be added to Mexichem’s existing Zephex brand of medical propellants, which make up around 75% of the inhalers produced worldwide, according to the press release.
“Since 1995 Zephex products have filled around 3.5 billion inhalers, helping to improve the lives of over 100 million people every year. This acquisition highlights our continued commitment to leading the market and will allow us to further support a valuable part of our customer’s product portfolios,” said Simon Gardner, general manager of Mexichem Fluor Medical Products, in a press release.